Atrophic Vaginitis Market is anticipated to grow at CAGR of 1.6% in the 7MM for the Study Period of 2019-32 | DelveInsight

The Atrophic Vaginitis market is expected to grow owing to the aging population and increase in disease awareness.
DelveInsight's Atrophic Vaginitis Market Insights report proffers a detailed comprehension of Atrophic Vaginitis market size by treatment, epidemiology, emerging therapies, Atrophic Vaginitis market share of the individual therapies, current and forecasted Atrophic Vaginitis market size from 2019 to 2032 segmented into 7MM (the USA, EU5 (the UK, Italy, Spain, France, and Germany), and Japan).

To know more about Atrophic Vaginitis Market Report: https://www.delveinsight.com/report-store/atrophic-vaginitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Atrophic Vaginitis: Overview
Atrophic Vaginitis, also called Vaginal Atrophy, is a condition where the lining of the vagina gets drier and thinner. This results in itching, burning, and pain during sex, among other Atrophic Vaginitis symptoms. The condition also includes urinary tract problems such as Urinary Tract Infections (UTIs) and frequent urination.

For further information on Market Impact by Therapies, Download the Atrophic Vaginitis Market sample @ https://www.delveinsight.com/sample-request/atrophic-vaginitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Atrophic Vaginitis Epidemiology Segmentation
The Atrophic Vaginitis Market Report proffers epidemiological analysis for the study period 2019-32 in the 7MM segmented into:
• Total Prevalent cases of Atrophic Vaginitis
• Total Diagnosed Cases of Atrophic Vaginitis
• Total Atrophic Vaginitis cases by severity
• Total Patients taking Prescription treatment

Know-how Atrophic Vaginitis Epidemiological Trends are going to look like in 2032 for the 7MM by downloading @ https://www.delveinsight.com/report-store/atrophic-vaginitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some of the essential features from the Atrophic Vaginitis Market Report:
• As per the DelveInsight estimates, in the year 2021, the total prevalent cases of Atrophic Vaginitis were 95.94 million cases in the 7MM, which are expected to grow during the study period.
• The Atrophic Vaginitis current treatment includes estrogen therapy: Imvexxy, hormone replacement therapy, Systemic selective estrogen receptor modulator: Osphena and DHEA: Intrarosa
• The total Atrophic Vaginitis market size in the United States accounted for USD 2700 million in 2021 which is expected to rise during the study period.
• Key Atrophic Vcaginitis companies suchas Shionogi, Hormos Medical, QuatRx Pharmaceuticals, Pantarhei Bioscience, Mithra Pharmaceuticals, Endoceutics, AMAG Pharmaceuticals, Bayer HealthCare Pharmaceuticals Inc., Theramex, and others are currently actively working in the Atrophic Vaginitis market.
• Key Atrophic Vaginitis therapies in the pipeline include Estetrol, DHEA: Intrarosa, and others.
• In January 2019, Duchesnay announced the FDA approval of the supplemental New Drug Application (sNDA) for Osphena (ospemifene) to expand its use to include treatment of moderate to severe vaginal dryness, a symptom of vulvar and vaginal atrophy, due to menopause.

Atrophic Vaginitis Market Outlook

Atrophic Vaginitis treatment begins with the use of over-the-counter measures such as lubricants and moisturizers, in the second line of treatment, patients use intravaginal estrogen. Intravaginal estrogen products, conjugated estrogen cream, estradiol cream, estradiol tablet, estradiol vaginal ring, and estradiol transdermal patch show equivocal relief of Atrophic Vaginitis symptoms and improvement in acidification of vaginal tissues.

Atrophic Vaginitis market dynamics are anticipated to change in the coming years owing to increase in the women in menopausal phase and increasing awareness among females for the disease. The acceptance of the disease as a health problem will be crucial for the growth of the Atrophic Vaginitis market.

Discover more about therapy set to grab substantial Atrophic Vaginitis market share @ https://www.delveinsight.com/report-store/atrophic-vaginitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Atrophic Vaginitis Pipeline Therapies and Key Companies
• Estetrol: Pantarhei Bioscience
• Prasterone Vaginal: Bayer/Endoceutics

Atrophic Vaginitis Market: Drivers and Barriers

In the past decade, research and development of diagnostic testing have allowed a modern treatment approach, giving rise to increasing awareness about Atrophic Vaginitis. In addition to that, the increasing prevalence of Atrophic Vaginitis cases, as well as the rise in the aging population, serve as certain factors for the Atrophic Vaginitis market surge in the coming years. On top of that, there's a very less competitive scenario in the Atrophic Vaginitis market, leading to the growth of existential companies as well as the entrance of new companies will also have sufficient scope in the
Atrophic Vaginitis market
On the contrary, several complications associated with the current Atrophic Vaginitis treatment options available are a factor anticipated as an obstruction in the growth of the Atrophic Vaginitis market. In addition to that, the Atrophic Vaginitis market players facing competition from generic drug manufacturers also serve as a potential drawback for the Atrophic Vaginitis market.

Know which Atrophic Vaginitis therapy is expected to score the touchdown first @ https://www.delveinsight.com/report-store/atrophic-vaginitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr


Scope of the Atrophic Vaginitis Market Report
• Study Period: 2019-32
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Atrophic Vaginitis Companies: Shionogi (OTCMKTS: SGIOY), Hormos Medical, QuatRx Pharmaceuticals, Pantarhei Bioscience, Mithra Pharmaceuticals (EBR: MITRA), Endoceutics, AMAG Pharmaceuticals, Bayer HealthCare Pharmaceuticals Inc. (OTCMKTS: BAYRY), Theramex
• Key Atrophic Vaginitis Marketed Therapies: Estetrol, DHEA: Intrarosa
• Therapeutic Assessment: Atrophic Vaginitis current marketed and emerging therapies
• Market Dynamics: Atrophic Vaginitis market drivers and barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Unmet Needs
• KOL's views
• Analyst's views
• Market Access and Reimbursement

Discover more about the future market share of Atrophic Vaginitis treatment therapies @ https://www.delveinsight.com/report-store/atrophic-vaginitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Contents
1 Key Insights
2 Report Introduction of Atrophic Vaginitis
3 Atrophic Vaginitis: Market overview at a glance
4 Executive Summary of Atrophic Vaginitis
5 Organizations contributing towards Atrophic Vaginitis
6 Disease Background and Overview of Atrophic Vaginitis
7 Management and Treatment of Atrophic Vaginitis
8 Atrophic Vaginitis Epidemiology and Patient Population
9 Atrophic Vaginitis Patient Journey
10 Atrophic Vaginitis Case Reports
11 Atrophic Vaginitis Marketed Therapies
12 Atrophic Vaginitis Emerging Therapies
13 Atrophic Vaginitis: 7 Major Market Analysis
14 Atrophic Vaginitis Market Outlook
15 Unmet Needs in Atrophic Vaginitis
16 KOL Views
17 Atrophic Vaginitis Market Drivers
18 Atrophic Vaginitis Market Barriers
19 Atrophic Vaginitis SWOT Analysis
20 Appendix
21 DelveInsight Capabilities
22 Disclaimer
23 About DelveInsight

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.